基本信息
浏览量:257
职业迁徙
个人简介
His main research interests are the identification of molecular, cell biological and epigenetic markers (1) to predict lymph node metastasis in patients with primary cancer of the oral cavity, (2) to predict response to (chemo) radiotherapy in head & neck cancer and cervical cancer; (3) to identify hypermethylated biomarkers as a novel potential diagnostic tool for early detection of cervical cancer; (4) to investigate the molecular mechanisms of resistance against targeted therapy; and (5) to develop new assays for the detection of circulating tumor DNA in cell-free plasma. He collaborates intensively with the departments of Gynaecological Oncology, Pulmonary Oncology, Maxillofacial Surgery and ENT within the UMCG. His latest research interest is the implementation of the detection and monitoring of tumor response and resistance to TKI-treatment in GIST and to TKI-/immunotherapy in NSCLC using mutation testing by digital droplet PCR and innovative NGS approaches in ctDNA from blood plasma. His research is embedded in the Cancer Research Center Groningen of the research institute of the UMCG and he acts as a principal investigator for several postdoctoral and PhD-student projects.
Besides projects supported by cancer foundations (KWF/Dutch Cancer Society, Cancer-ID, ZonMW and CTMM/Center for Translational Molecular Medicine), between 2012-2020 he has several collaborations with biotech companies (MDXHealth/Oncomethylome, Abbott, Astrazeneca, Invitae/Archer, Bayer, Pfizer, Biocartis, BMS, Bio-Rad, Roche, Agena Bioscience, CC Diagnostics, Boehringer Ingelheim). He is an active member of the Dutch Society of Pathology, American Association of Cancer Research, the Association of Molecular Pathology, American Society of Clinical Oncology, European Society of Pathology, Dutch Society of Oncology; section of Clinical, Molecular and Experimental Pathology, among others.
Within the department of Pathology he is the head of the Laboratory for Molecular Pathology performing molecular testing for clinicians at the UMCG and the North part of the Netherlands. Since 1997 he is active in several (inter)national committees on implementing molecular diagnostic pathology. He is the founder and active member of the national committee Molecular Diagnostic in Pathology and the “landelijke Vereniging voor Moleculaire Diagnostiek in de Gezondheidszorg”. He co-authored several guidelines on molecular pathology, is an active member in the Quality Control group organizing annual national proficiency testing as well as assessing EQA on both clinical tissues and cell-free plasma samples (for SKML, QCMD, Euroclonality, IQNPath and ESP) and acts regular upon invitation of companies in Molecular Pathology as consultant or advisor regarding new development in molecular diagnostics. He also performed external audits as expert in Molecular Pathology for the Raad van Accreditatie on ISO15189. More recently, he is senior expert/advisor for Molecular Pathology for cieBAG, ZIN/VWS, zorgverzekeringen, missiePTO, IKNL-platform PTO in the Nehterlands.
Between 2012-2020 (31-12-2020) he received honoraria for expertise or scientific advisory board/consultancy (on request) from MSD/Merck, AstraZeneca, Roche, Pfizer, Novartis, Bayer, BMS, Lilly, Amgen, Qiagen, BioCartis, Illumina, Agena Bioscience, CC Diagnostics, QCMD, ESP, IQNPATH, Cancer-ID, Janssen Cilag (Johnson&Johnson), Diaceutics (all fees to UMCG)
Between 2012-2020 (31-12-2020) he received speaker’s fee (on invitation) from Bio-Rad, Abbott, Novartis, Roche, Biocartis, Agena Bioscience, Illumina, Pfizer, Astrazeneca (all fees to UMCG)
Between 2012-2020 (31-12-2020) he received unrestricted project grants (financial and/or in kind) from MDXHealth/Oncomethylome, Pfizer, Biocartis, Cancer-ID, BMS, Astrazeneca, Invitae/Archer, Bayer, Bio-Rad, Roche, Agena Bioscience, CC Diagnostics, Boehringer Ingelheim, Qiagen, Promega, TATAA (all fees to UMCG)
Between 2012-2020 (31-12-2020) he received travel reimbursements (on invitation) from Agena Bioscience, BioRad, Abbott, Illumina, Astrazeneca, Roche and Hologic
Besides projects supported by cancer foundations (KWF/Dutch Cancer Society, Cancer-ID, ZonMW and CTMM/Center for Translational Molecular Medicine), between 2012-2020 he has several collaborations with biotech companies (MDXHealth/Oncomethylome, Abbott, Astrazeneca, Invitae/Archer, Bayer, Pfizer, Biocartis, BMS, Bio-Rad, Roche, Agena Bioscience, CC Diagnostics, Boehringer Ingelheim). He is an active member of the Dutch Society of Pathology, American Association of Cancer Research, the Association of Molecular Pathology, American Society of Clinical Oncology, European Society of Pathology, Dutch Society of Oncology; section of Clinical, Molecular and Experimental Pathology, among others.
Within the department of Pathology he is the head of the Laboratory for Molecular Pathology performing molecular testing for clinicians at the UMCG and the North part of the Netherlands. Since 1997 he is active in several (inter)national committees on implementing molecular diagnostic pathology. He is the founder and active member of the national committee Molecular Diagnostic in Pathology and the “landelijke Vereniging voor Moleculaire Diagnostiek in de Gezondheidszorg”. He co-authored several guidelines on molecular pathology, is an active member in the Quality Control group organizing annual national proficiency testing as well as assessing EQA on both clinical tissues and cell-free plasma samples (for SKML, QCMD, Euroclonality, IQNPath and ESP) and acts regular upon invitation of companies in Molecular Pathology as consultant or advisor regarding new development in molecular diagnostics. He also performed external audits as expert in Molecular Pathology for the Raad van Accreditatie on ISO15189. More recently, he is senior expert/advisor for Molecular Pathology for cieBAG, ZIN/VWS, zorgverzekeringen, missiePTO, IKNL-platform PTO in the Nehterlands.
Between 2012-2020 (31-12-2020) he received honoraria for expertise or scientific advisory board/consultancy (on request) from MSD/Merck, AstraZeneca, Roche, Pfizer, Novartis, Bayer, BMS, Lilly, Amgen, Qiagen, BioCartis, Illumina, Agena Bioscience, CC Diagnostics, QCMD, ESP, IQNPATH, Cancer-ID, Janssen Cilag (Johnson&Johnson), Diaceutics (all fees to UMCG)
Between 2012-2020 (31-12-2020) he received speaker’s fee (on invitation) from Bio-Rad, Abbott, Novartis, Roche, Biocartis, Agena Bioscience, Illumina, Pfizer, Astrazeneca (all fees to UMCG)
Between 2012-2020 (31-12-2020) he received unrestricted project grants (financial and/or in kind) from MDXHealth/Oncomethylome, Pfizer, Biocartis, Cancer-ID, BMS, Astrazeneca, Invitae/Archer, Bayer, Bio-Rad, Roche, Agena Bioscience, CC Diagnostics, Boehringer Ingelheim, Qiagen, Promega, TATAA (all fees to UMCG)
Between 2012-2020 (31-12-2020) he received travel reimbursements (on invitation) from Agena Bioscience, BioRad, Abbott, Illumina, Astrazeneca, Roche and Hologic
研究兴趣
论文共 453 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Clinical chemistryno. 1 (2024): 220-233
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicineno. s1 (2024): S327-S340
Paul van der Leest, Pim Rozendal, John Hinrichs,Carel J. M. van Noesel,Karen Zwaenepoel,Birgit Deiman, Cornelis J. J. Huijsmans,Ronald van Eijk,Ernst Jan M. Speel, Rick J. van Haastert,Marjolijn J. L. Ligtenberg, Ron H. N. van Schaik,
CLINICAL CHEMISTRY (2024)
crossref(2023)
H. C. Donker,B. van Es, M. Tamminga,G. A. Lunter,L. C. L. T. van Kempen,E. Schuuring, T. J. N. Hiltermann,H. J. M. Groen
Lung cancer (Amsterdam, Netherlands) (2023): 107286-107286
FRONTIERS IN ONCOLOGY (2023): 1136221-1136221
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn